Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning conveyed its support for the Food & Drug Administration’s (“FDA”) February 21 statement titled “Smoking Cessation and Related Indications: Developing Nicotine Replacement Therapy Drug Products”. The FDA’s statement outlined the development of safe and effective novel nicotine replacement therapies to help smokers quit cigarettes, stating that “novel products with different characteristics or routes of nicotine delivery have the potential to offer additional opportunities for health-concerned smokers interested in quitting.” Lexaria recently entered a partnership with a leading tobacco company to use DehydraTECH(TM) technology to develop new oral nicotine products. This technology could provide a nicotine delivery method that harmonizes with current FDA policies while avoiding the grave health consequences related to smoking cigarettes and preserving the consumers’ choice.
To view the full FDA statement, visit http://ibn.fm/4RIy8
To view the full press release, visit http://ibn.fm/eC8YC
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH(TM) delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.